State Street Health Care Select Sector SPDR ETF (XLV)
| Assets | $43.12B |
| Expense Ratio | 0.08% |
| PE Ratio | 23.77 |
| Shares Out | 267.02M |
| Dividend (ttm) | $2.48 |
| Dividend Yield | 1.55% |
| Ex-Dividend Date | Dec 22, 2025 |
| Payout Ratio | 36.74% |
| 1-Year Return | +8.38% |
| Volume | 14,244,184 |
| Open | 156.74 |
| Previous Close | 157.42 |
| Day's Range | 156.71 - 160.24 |
| 52-Week Low | 127.35 |
| 52-Week High | 160.59 |
| Beta | 0.61 |
| Holdings | 63 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe State Street Health Care Select Sector SPDR ETF (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
58.08% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 14.24% |
| Johnson & Johnson | JNJ | 10.29% |
| AbbVie Inc. | ABBV | 6.97% |
| Merck & Co., Inc. | MRK | 5.19% |
| UnitedHealth Group Incorporated | UNH | 4.55% |
| Amgen Inc. | AMGN | 3.58% |
| Abbott Laboratories | ABT | 3.55% |
| Thermo Fisher Scientific Inc. | TMO | 3.43% |
| Intuitive Surgical, Inc. | ISRG | 3.15% |
| Gilead Sciences, Inc. | GILD | 3.13% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.65682 | Dec 24, 2025 |
| Sep 22, 2025 | $0.62487 | Sep 24, 2025 |
| Jun 23, 2025 | $0.63038 | Jun 25, 2025 |
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62166 | Dec 26, 2024 |
| Sep 23, 2024 | $0.57723 | Sep 25, 2024 |
News
Sector Rotation: Healthcare XLV Should Be The Next Stop
The healthcare sector is poised to benefit next from the ongoing market rotation to value and defensives. XLP's rapid ascent has led to overbought technicals and a valuation premium, with forward P/E ...
Time for Investors to Get Defensive. Sell Staples and Buy Healthcare.
The market is shaky, software stocks have gone off a cliff, and semiconductor stocks are giving back some of their gain. It's time to tweak your portfolio.
Do More for Your Core: A Tactical Roadmap for Sector Investing
Sector investing — it's a typical strategy for advisors if their clients are looking beyond broad market exposure by targeting a specific sector. The concept is fairly straightforward, but implementin...
Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More
Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and di...
Energy Leads S&P Sectors in January
Three of the smallest sectors in the S&P 500 delivered the index's strongest performance in January, while the two largest sectors weighed on returns. The broad market index gained modest ground last ...
XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?
The Health Care sector, lagging in recent years, is positioned for mean reversion and potential outperformance in 2026. XLV offers low-cost, passive exposure to large-cap Health Care, with a 1.4-1.8% ...
My Ultimate Dividend ETF Combo For 5%+ Yield And 10%+ Annual Growth
A golden yield-and-growth combo is something most investors assume they'll rarely find. Defensive income machines keep quietly compounding at double-digit rates. This trio could change how you think a...
As AI Valuations Stretch, Health Care ETFs Step Into The Growth Spotlight
Health care ETFs could emerge as one of the stronger performers in 2026 as investors grow cautious about pricey AI stocks.
Mizuho's Jared Holz on why he is bullish on biotech heading into 2026
Jared Holz, Mizuho, joins 'Power Lunch' to talk how to play healthcare and biotech moving into 2026.
Historic Health Care Relative Strength
While stocks are getting off to a quiet start to December, the S&P 500 staged a solid recovery in the final week of November to manage a modest 13 bps gain on the month. A majority of sectors actually...
XLV: The Simple Case For Overweighting U.S. Health Care
The H ealth Care Select Sector SPDR is comprised of all the Health Care stocks inside the S&P 500 Index. Its expense ratio is only 0.08% and XLV has $41.2B in AUM. The simple case for overweighting U....
Healthcare ETFs: I Prefer VHT's Growth To XLV's Stability
Vanguard Health Care ETF and Health Care Select Sector SPDR Fund both benefit from healthcare innovation tailwinds, earning a buy rating. VHT offers broader diversification and greater exposure to sma...
Josh Brown's ‘best stocks in the market': Health Care
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he's spotlighting Health Care in his "best stocks in the market." The Committee debates their health care s...
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
'Fast Money' traders talk how to play biopharma space
The 'Fast Money' traders talk how to play biopharma space.
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Momentum and private assets: The trends driving ETFs to record inflows
ETF inflows are already at record annual flows. Todd Rosenbluth, VettaFi head of research, on what's driving the momentum and the trends that are standing out.
Schwab IMPACT 2025: Record $13T in ETFs & What's Next for ETF Assets
Matt Camuso, Head of ETF Solutions at BNY Investments, says there are $13 trillion of assets in ETFs. That's compared to $5 trillion a year prior.
State Street's Anna Paglia on why the firm is shifting from ETFs to mutual funds
Anna Paglia, State Street Investment Research CBO and chief business officer, joins CNBC's Dom Chu on the type of assets and ETFs State Street is seeing the flows into. She also shares why the firm is...
Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin
Right now ahead of Halloween, the real suspense might be in ETF investing strategies. With markets seesawing between hopes for rate cuts and the resilience of earnings, investors are dusting off one o...
The Utterly Tranquil Feeling Of Watching Your Passive Income Grow
Dividend growth investing offers reliable, passive income and personal tranquility, more so than non-dividend strategies and rental property investing. Current market valuations, especially in Big Tec...